Jeffrey Trigilio Cullinan Oncology, Inc. (CGEM) insider trading activity

Jeffrey Trigilio is Chief Financial Officer of Cullinan Oncology, Inc.. Currently has a direct ownership of 133,919 shares of CGEM, which is worth approximately $2.11 Million. The most recent transaction as insider was on Feb 22, 2024, when has been sold 50,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 134K

0% 3M change

51.9% 12M change

Total Value Held $2.11 Million

Jeffrey Trigilio Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 22 2024	BUY Grant, award, or other acquisition	-	50,000 Added 27.19%	133,919 Common Stock
Dec 21 2023	SELL Open market or private sale	$16,320 $8.5 p/Share	1,920 Reduced 2.24%	83,919 Common Stock
Dec 18 2023	SELL Open market or private sale	$3,271 $8.22 p/Share	398 Reduced 0.46%	85,839 Common Stock
Dec 12 2023	SELL Open market or private sale	$15,042 $7.81 p/Share	1,926 Reduced 2.18%	86,237 Common Stock
Jun 30 2023	BUY Grant, award, or other acquisition	$21,247 $9.08 p/Share	2,340 Added 2.59%	88,163 Common Stock
Jun 20 2023	SELL Open market or private sale	$5,163 $12.94 p/Share	399 Reduced 0.46%	85,823 Common Stock
Jun 12 2023	SELL Open market or private sale	$4,182 $13.11 p/Share	319 Reduced 0.37%	86,222 Common Stock
May 18 2023	SELL Open market or private sale	$3,495 $8.76 p/Share	399 Reduced 0.46%	86,541 Common Stock
May 12 2023	SELL Open market or private sale	$3,046 $8.78 p/Share	347 Reduced 0.4%	86,940 Common Stock
Apr 18 2023	SELL Open market or private sale	$4,262 $10.71 p/Share	398 Reduced 0.45%	87,287 Common Stock
Apr 12 2023	SELL Open market or private sale	$3,249 $10.22 p/Share	318 Reduced 0.36%	87,685 Common Stock
Mar 20 2023	SELL Open market or private sale	$4,516 $11.32 p/Share	399 Reduced 0.45%	88,003 Common Stock
Feb 17 2023	BUY Grant, award, or other acquisition	-	47,000 Added 34.71%	88,402 Common Stock
Dec 30 2022	BUY Grant, award, or other acquisition	$1,802 $8.97 p/Share	201 Added 0.48%	41,402 Common Stock
Jun 30 2022	BUY Grant, award, or other acquisition	$15,816 $10.9 p/Share	1,451 Added 3.4%	41,201 Common Stock
Feb 11 2022	BUY Grant, award, or other acquisition	-	37,500 Added 48.54%	39,750 Common Stock
Oct 15 2021	SELL Open market or private sale	$200,000 $25.0 p/Share	8,000 Reduced 78.05%	2,250 Common Stock
Oct 15 2021	BUY Exercise of conversion of derivative security	$34,400 $4.3 p/Share	8,000 Added 43.84%	10,250 Common Stock
Sep 08 2021	SELL Open market or private sale	$425,100 $28.34 p/Share	15,000 Reduced 86.96%	2,250 Common Stock
Sep 08 2021	BUY Exercise of conversion of derivative security	$64,500 $4.3 p/Share	15,000 Added 46.51%	17,250 Common Stock
Jan 12 2021	BUY Open market or private purchase	$47,250 $21.0 p/Share	2,250 Added 50.0%	2,250 Common Stock

Jeffrey Trigilio

Chief Financial Officer

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CGEM shares.

Notify only if

Value

Insider Trading

Get notified when an Cullinan Oncology, Inc. insider buys or sells CGEM shares.

Notify only if

Operation

Value

Type

News

Receive news related to Cullinan Oncology, Inc.

Track Activities on CGEM

Account